# Response of FGFR-2 Positive Adenoid Cystic Carcinoma to Futibatinib: A Case Report

## TL;DR

A patient with a specific FGFR-2 mutation in adenoid cystic carcinoma responded well to a new drug called futibatinib, suggesting a potential personalized treatment approach.

## Contribution

This case report demonstrates the effectiveness of futibatinib in treating FGFR-2 positive adenoid cystic carcinoma.

## Key findings

- A patient with FGFR-2 mutation in ACC showed significant response to futibatinib.
- The case suggests personalized treatment options for ACC patients with similar genetic alterations.
- Further research is needed to optimize treatment protocols and overcome resistance.

## Abstract

Adenoid cystic carcinoma (ACC) is an uncommon and aggressive head and neck cancer mainly affecting minor salivary glands. It affects more women than men in their 60s and 70s. The tumor is typically locally aggressive and has a high rate of distant metastatic disease. This report unveils a potential avenue for targeted therapy for the management of metastatic disease: a patient with ACC who harbored a specific fibroblast growth factor receptor 2 (FGFR-2) mutation and responded significantly to a novel FGFR-2 inhibitor. This finding could pave the way for personalized treatment options for ACC patients with similar genetic alterations. Nevertheless, the use of futibatinib requires further investigation to optimize treatment protocols, including exploring combination therapies, identifying predictive biomarkers for treatment response, and developing strategies to overcome potential resistance.